⚡️ My PhD thesis is on arXiv! ⚡️
To quote my examiners it is "the textbook of neural differential equations" - across ordinary/controlled/stochastic diffeqs.
w/ unpublished material:
- generalised adjoint methods
- symbolic regression
- + more!
https://t.co/Pm5l6FhEED
v🧵 1/n
Iso did a $5B raise, okay, that's nice I guess.
Where are the drugs? Iso promised the cure to all diseases. Five years and $7B+ further along, and Iso doesn't seem to have cured a single one?
So I have mixed feelings about IsoDDE. It's an AF4, it's much better on hard problems, and I don't want to understate their technical achievement.
But also, it's been five years since founding, and success is measured in drugs, not models. Where are the drugs? 1/
Biggest vacuum in biotech funding to me seems to be firms that can help put together meaningful Seed rounds.
A lot of pre-seed and small Seed investors → Big vacuum → larger biotech investors that need to see a robust data package before coming in.
Loads of very exciting technologies floating around, but the companies behind them lack the resources to really validate them.
With the crazy advances in AI and bio infrastructure, I don't think these even need to be that big of a round -- think $10–15M could be quite transformative for many companies.
@fordycelab@DidiKieran About a year old now but https://t.co/JrtrE9K5ji is a great reference on minibinder design
More recently we've seem similar results from the anthropic scorpion venom project, Adaptyv competitions etc
Having started a biotech co in the past two years, the recent Mithril Medicine news felt pretty unsurprising.
When people ask me what surprised me most about being a biotech founder, I always say that I dramatically overestimated the number of people I would need to hire. AI has been transformational here, but so has the excessive build-out of CRO capabilities in the COVID ZIRP era making CRO prices dramatically cheaper than they would be otherwise. Operations, chemistry, tox, and most preclinical work can all be outsourced for 20-60% of the price of building the same capabilities in house. The core platform still needs hands-on internal work, but if you're building a very traditional asset-flip biotech startup, then there is no core platform to begin with.
There is some sacrifice in terms of speed over the long-term, but the combo of AI+automation+CROs suddenly allows biotech startups to create value on previously-challenging VC fund timelines. My prediction is that a biotech startup model consisting of a tiny team of 1-5 people is going to become fairly standard in the near-term future.
mfw
>biology is just a data problem
>collect enough omics, simulate the whole cell
>read about humanin
>peptide encoded inside the mitochondrial 16S rRNA gene
>the same sequence is also a structural part of the ribosome
>24 aa if the cytosol translates it, 21 aa if the mitochondria do
>because mitochondria run a different genetic code
>and start translation with N-formylmethionine instead of plain methionine
>nobody's fully sure which one actually makes it
>also 13 nuclear copies that might make their own versions
>gets secreted into the blood
>hits cell-surface receptors
>one of them is literally a mitochondria detector
>also gets taken back up
>binds Bax inside the cell to block apoptosis
>discovered by screening surviving brain tissue from an alzheimer's patient
>open my cell model schema
>compartment: yes
>molecule_type: rRNA, peptide, hormone
>length: depends who's asking
@SimonDBarnett fwiw I find myself living in a perpetual state of future shock about AI+bio as well
biopharma is traditionally a slow-moving industry – I don't think they're right, but I am sympathetic/unsurprised.
@dshahh I mean in the sense of antibody production (what you'd normally do in CHO cells etc).
(Not sure if we're talking past each other, maybe you're highlighting that there are approaches other than direct antibody production? In which case, agreed, at least for some problems.)
Someone needs to raise $200M to launch cell-free (non-E. coli) GMP manufacture
clearly the best way to make n=1 cancer treatments / any experimental low-batch-size stuff
💥 Introducing Warp Sciences, a new company applying AI and robotics to help the world develop new medicines faster.
We’ve raised a $215M Series A led by @lightspeedvp to bring frontier AI out of the browser and into the lab, and build scientific capacity here in America.
I co-founded Warp with my long-time friend @dpatil, FAIR co-founder @manohar_paluri, and drug hunter Sol Reisberg. The early team is full of incredible people like @bkspears9, who helped achieve Q>1 fusion at LLNL.
Update: I've now *also* had multiple JAX-for-{fusion,molecular dynamics,...} companies ask me for referrals in the exact same way.
I need to start hosting a job board haha
I've had [what feels like] approximately every AI+bio company ask me for any talent referrals recently. It's a seller's market right now.
If you have at least a small portfolio (strong PhD or a couple years in industry) + are willing to work at least a 9-7 then you're golden.
1/2
What the 'neopharma' discussion misses is that this is a class of companies, as "software" is a class. The VC pitch is the layer of detail below. Modality/in vivo data/etc.
If you want to distinguish the serious/unserious, ask them what their GLP-tox strategy is.
A lot of this is just Stanford/ Valley money
Like it's a bit inconsequential that these companies are AI x Bio. It's more of the fact that they are valley ppl. AI x Bio outside the valley or without deep Boston ties have no shot at raising this kind of money even if they're doing the same thing verbatim
The degree of target clustering in pharma right now is absolute madness. How is this not objectively idiotic?
The pendulum will swing back to unique/novel MoAs eventually…it just has to.
Right now you can get VALIDATED novel/unique MoAs for less than some of these me-80 drugs in some cases. The system seems broken.